Literature DB >> 26067083

Is prolactin the missing link in adipose tissue dysfunction of polycystic ovary syndrome patients?

Alice Albu1,2, Suzana Florea3, Simona Fica4,3.   

Abstract

The aims of the study were to evaluate whether adiposity was among the determinants of circulating prolactin levels and to determine whether serum prolactin independently predicted metabolic abnormalities in patients with polycystic ovary syndrome (PCOS). A total of 322 PCOS patients with normal serum prolactin levels were recruited between January 2007 and January 2014. Anthropometric, metabolic, and hormonal parameters were measured in all of the patients. HOMA-IR was calculated as an index of insulin resistance. Serum prolactin was negatively correlated with age (p < 0.0001), all the adiposity indices [body mass index p < 0.0001; waist circumference p < 0.0001; waist-hip ratio (WHR) p < 0.0001], visceral adiposity index (VAI, p = 0.043), fasting insulinemia (p = 0.002), and HOMA-IR (p = 0.002), and was positively correlated with serum adiponectin (p = 0.034), but not with circulating androgens or serum leptin levels. Serum adiponectin, but not HOMA-IR or fasting insulinemia, was independently associated with serum prolactin after adjustment for age, leptin, and anthropometrical adiposity parameters. Of the adiposity parameters, only WHR and VAI were independent predictors of serum prolactin after adjustment for adiponectin. Circulating prolactin was also negatively correlated with fasting glycemia (only in patients with normal glucose metabolism, p = 0.037) and was inversely correlated with the presence of metabolic syndrome (p < 0.001), but this association was not maintained after adjustment for possible confounders. In PCOS patients, serum prolactin level was related to adipose tissue quantity and function, and adiponectin was a possible mediator of this relationship. Low serum prolactin levels were associated with an unfavorable metabolic profile, but this association seemed to be due to the complex interplay among prolactin, adiposity, and insulin resistance rather than to a direct metabolic effect of prolactin.

Entities:  

Keywords:  Adiponectin; Adiposity dysfunction; Polycystic ovary syndrome; Prolactin

Mesh:

Substances:

Year:  2015        PMID: 26067083     DOI: 10.1007/s12020-015-0655-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  40 in total

Review 1.  Prolactin and adipose tissue.

Authors:  Nadège Carré; Nadine Binart
Journal:  Biochimie       Date:  2013-10-08       Impact factor: 4.079

2.  Larger hip circumference independently predicts health and longevity in a Swedish female cohort.

Authors:  L Lissner; C Björkelund; B L Heitmann; J C Seidell; C Bengtsson
Journal:  Obes Res       Date:  2001-10

3.  Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study.

Authors:  J C Seidell; L Pérusse; J P Després; C Bouchard
Journal:  Am J Clin Nutr       Date:  2001-09       Impact factor: 7.045

4.  Serum prolactin concentrations determine whether they improve or impair β-cell function and insulin sensitivity in diabetic rats.

Authors:  Sunmin Park; Da Sol Kim; James W Daily; Sung-Hoon Kim
Journal:  Diabetes Metab Res Rev       Date:  2011-09       Impact factor: 4.876

5.  Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance.

Authors:  Louise Mannerås-Holm; Henrik Leonhardt; Joel Kullberg; Eva Jennische; Anders Odén; Göran Holm; Mikael Hellström; Lars Lönn; Gunilla Olivecrona; Elisabet Stener-Victorin; Malin Lönn
Journal:  J Clin Endocrinol Metab       Date:  2010-11-17       Impact factor: 5.958

Review 6.  Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Lisa J Moran; Marie L Misso; Robert A Wild; Robert J Norman
Journal:  Hum Reprod Update       Date:  2010-02-16       Impact factor: 15.610

7.  Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction.

Authors:  Giovanni Corona; Edoardo Mannucci; Emmanuele A Jannini; Francesco Lotti; Valdo Ricca; Matteo Monami; Valentina Boddi; Elisa Bandini; Giancarlo Balercia; Gianni Forti; Mario Maggi
Journal:  J Sex Med       Date:  2009-02-10       Impact factor: 3.802

8.  The role of growth hormone, prolactin and insulin-like growth factors in the regulation of rat mammary gland and adipose tissue metabolism during lactation.

Authors:  M C Barber; R A Clegg; E Finley; R G Vernon; D J Flint
Journal:  J Endocrinol       Date:  1992-11       Impact factor: 4.286

9.  Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?

Authors:  Lisa Balbach; Henri Wallaschofski; Henry Völzke; Matthias Nauck; Marcus Dörr; Robin Haring
Journal:  BMC Endocr Disord       Date:  2013-03-21       Impact factor: 2.763

Review 10.  Visceral adiposity index: an indicator of adipose tissue dysfunction.

Authors:  Marco Calogero Amato; Carla Giordano
Journal:  Int J Endocrinol       Date:  2014-04-14       Impact factor: 3.257

View more
  4 in total

1.  Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans.

Authors:  Antonio J Ponce; Tomás Galván-Salas; Ricardo M Lerma-Alvarado; Xarubet Ruiz-Herrera; Tomás Hernández-Cortés; Rodrigo Valencia-Jiménez; Laura E Cárdenas-Rodríguez; Gonzalo Martínez de la Escalera; Carmen Clapp; Yazmín Macotela
Journal:  Endocrine       Date:  2020-01-09       Impact factor: 3.633

2.  Association of Serum Prolactin With Type 2 Diabetes Mellitus: A Comparative Cross-Sectional Study From South India.

Authors:  C A Jayashankar; Akshatha Manohar; Amey Joshi; Vignesh Dwarakanathan; Venkata Bharat Kumar Pinnelli; Vijaya Sarathi; Lakshmi Meghana Gada
Journal:  Cureus       Date:  2022-04-01

Review 3.  The beneficial metabolic actions of prolactin.

Authors:  Yazmín Macotela; Xarubet Ruiz-Herrera; Dina I Vázquez-Carrillo; Gabriela Ramírez-Hernandez; Gonzalo Martínez de la Escalera; Carmen Clapp
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-23       Impact factor: 6.055

Review 4.  Metabolic effects of prolactin and the role of dopamine agonists: A review.

Authors:  Polly Kirsch; Jessica Kunadia; Shruti Shah; Nidhi Agrawal
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-30       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.